Simmons 2000.
| Methods | Open, no ITT | |
| Participants | Household contacts, New Zealand | |
| Interventions | Rifampicin: 600 mg, children > 1 month, 10 mg/kg versus IM ceftriaxone: 250 mg < 12 years, 125 mg | |
| Outcomes | Morbidity, eradication, eradication of serogroup B, adverse effects Follow‐up: 6 days | |
| Notes | Data presented for carriers. Main serogroup: B | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | Unclear |
| Blinding of participants and personnel (performance bias) All outcomes | High risk | Open |
| Blinding of outcome assessment (detection bias) All outcomes | High risk | Open |
| Incomplete outcome data (attrition bias) All outcomes | Unclear risk | No ITT |
| Selective reporting (reporting bias) | Low risk | No evidence |
| Other bias | Low risk | No evidence |
f/u: follow‐up IM: intramuscular ITT: intention‐to‐treat